Hamamatsu Photonics K.K., founded in 1953 is a global leader in optical and sensor technology for scientific, medical, and industrial applications. At the heart of its Central Research Laboratory’s Biophotonics division lies the CAMP (cAMP photonics) initiative, which centers on cutting-edge optogenetic tools for precise intracellular cyclic AMP modulation. The flagship products under this initiative are the OaPAC360 and OaPAC348 photoactivated adenylyl cyclase variants, which generate cAMP inside live cells upon low‑intensity blue‑light exposure—providing researchers with finely tuned spatiotemporal control of signaling dynamics without relying on pharmacological agents. Developed to overcome limitations of the wild‑type OaPAC’s low light sensitivity and phototoxicity, these user‑friendly mutants offer enhanced illumination responsiveness for applications in neuronal morphogenesis, cell signaling, and disease modeling ([hamamatsu.com][2]). By integrating advanced photonics, opto-biology, and bioassay technologies, Hamamatsu’s CAMP products exemplify the company’s broader mission to harness the power of light in life sciences—delivering high-precision tools that push the frontiers of cellular and molecular research.
